-
Ruxolitinib
Zita reAPI Indication Innovator Patent Expiry Date (The US) Ruxolitinib Myelofibrosis Novartis Chikunguru. 6, 2024 -
Crisaborole
Zita reAPI Indication Innovator Patent Expiry Date (The US) Crisaborole Atopic Dermatitis uye Eczema Pfizer Jun. 11, 2026 -
Relugolix
Zita reAPI Indication Innovator Patent Expiry Date (The US) Relugolix Kenza yeprostate Takeda uye ASKA Ndira 24, 2024 -
Vericiguat
Zita reAPI Indication Innovator Patent Expiry Date (The US) Vericiguat Kukundikana kwemoyo Bayer uye MSD Chivabvu.24, 2031 -
Abrocitinib
Zita reAPI Indication Innovator Patent Expiry Date (The US) Abrocitinib Atopic Dermatitis Pfizer Kukadzi.11, 2034 -
Rimegepant
Zita reAPI Indication Innovator Patent Expiry Date (The US) Rimegepant Migraine musoro Biohaven Kukadzi 22, 2031 -
Elagolix 834153-87-6
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP ElagolixCAS:834153-87-6 Endometriosis Mumba -
Relugolix 737789-87-6
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Ribociclib CAS: 737789-87-6 Antineoplastic Mumba -
Venetoclax 1257044-40-8
Zita reAPI Indication Innovator Patent Expiry Date (The US) Venetoclax 1257044-40-8 CLL Abbvie Jun.27,2031 -
Velpatasvir (PVP)
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Velpatasvir (PVP) HCV Mumba √ -
Thalidomide
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Thalidomide Oncology mushonga USP/EP -
Ticagrelor
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Ticagrelor Anticoagulant Mumba 28984 √
